The decision hands Moderna its second-only product approval to date after its Covid jab, which has generated more than $40bn in revenue. Its blockbuster Covid shot propelled the Boston-based ...
Synopsys VC Verification IP (VIP) for Fibre Channel is designed to thoroughly verify Fibre Channel designs using both random and directed simulation. The Fibre Channel VIP provides full protocol ...
Moderna Inc. gained US approval for its RSV vaccine in older adults, giving the biotech company a second product as it seeks to move beyond its reliance on the fading market for Covid-19 shots ...
The Food and Drug Administration on Friday approved a third vaccine for respiratory syncytial virus, clearing a shot from biotechnology company Moderna ... in some cases leading to death. The virus ...
Moderna Inc. gained U.S. approval for its RSV vaccine in older adults, giving the biotech company a second product as it seeks to move beyond its reliance on the fading market for COVID-19 shots. The ...
Moderna Inc.’s respiratory syncytial virus vaccine for older adults received U.S. regulatory approval, the company said Friday, marking the first time a messenger RNA vaccine has been approved ...
Biotech firm Moderna (Nasdaq: MRNA) has won ... vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a ...
Covid-19 cases are relatively low ... s decision on the composition of the vaccine. Animal and lab studies show that shots made by Pfizer/BioNTech, Moderna and Novavax that target the JN.
its first non-Covid product, which could give the company a much-needed boost as pandemic sales have plunged. The U.S. Food and Drug Administration approved Moderna’s vaccine to protect against ...